Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2020

View Archived Issues

Prying mantis identifies disease genes

T-cell mutations contribute to GvHD

TLR5 is a therapeutic target for treating chronic colonic hypersensibility

NIH initiates ACTT 2 study of remdesivir plus baricitinib in patients with COVID-19

Novel peptide-targeted approach improves potency of anticancer drugs

PK and PD data presented for OPL-002 in healthy volunteers

CPU-025 demonstrates promising efficacy in mouse model of diabetes

Array BioPharma discloses new PTPN11 inhibitors

Dana-Farber Cancer Institute, Voronoi patent wild-type and mutant LRRK2 inhibitors

New histone-lysine N-methyltransferase SMYD3 inhibitors identified at Epizyme

Wild-type and mutant RET inhibitors identified at Medshine Discovery

Dual adenosine A2A/A2B receptor antagonists described by Merck KGaA

Via gene therapy, follistatin fights fat's fallout

New POLG genetic variant found in SANDO syndrome

ONSET-2 trial of OC-01 in dry eye disease meets primary endpoint

Phase III study of mavacamten in obstructive hypertrophic cardiomyopathy meets endpoints

Kiniksa reports data on mavrilimumab for COVID-19 and vixarelimab for pruritus

Boehringer Ingelheim studies BI-456906 for type 2 diabetes in new phase II trial

Canakinumab studied in phase III for CRS in patients with COVID-19-induced pneumonia

Enrollment underway for first-in-human study of BRAF inhibitor ABM-1310 in advanced solid tumors

Ustekinumab efficacy demonstrated in pediatric Crohn's disease patients

Phase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors

FDA clears IND for phase Ib/IIa study of HST-001 for androgenic alopecia

Phase III study of Sarclisa in relapsed multiple myeloma meets primary endpoint

Genfit reports phase III interim data on elafibranor in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...